default author photo

Xia-Juan Huan

Chinese Academy of Sciences (CAS) - Division of Anti-Tumor Pharmacology

Beijing

China

SCHOLARLY PAPERS

2

DOWNLOADS

79

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Glycogen Synthase Kinase 3β Inhibition Synergizes with PARP Inhibitors Through the Induction of Homologous Recombination Deficiency in Colorectal Cancer

Number of pages: 44 Posted: 27 Aug 2020
Ning Zhang, Yu-Nan Tian, Li-Na Zhou, Meng-Zhu Li, Shan-Shan Song, Xia-Juan Huan, Xu-Bing Bao, Ao Zhang, Ze-Hong Miao and Jin-Xue He
Chinese Academy of Sciences (CAS) - Division of Anti-Tumor Pharmacology, Chinese Academy of Sciences (CAS) - Division of Anti-Tumor Pharmacology, Chinese Academy of Sciences (CAS) - Division of Anti-Tumor Pharmacology, Chinese Academy of Sciences (CAS) - Division of Anti-Tumor Pharmacology, Chinese Academy of Sciences (CAS) - Division of Anti-Tumor Pharmacology, Chinese Academy of Sciences (CAS) - Division of Anti-Tumor Pharmacology, Chinese Academy of Sciences (CAS) - Division of Anti-Tumor Pharmacology, Chinese Academy of Sciences (CAS) - Department of Medicinal Chemistry, Chinese Academy of Sciences (CAS) - Division of Anti-Tumor Pharmacology and Chinese Academy of Sciences (CAS) - Division of Anti-Tumor Pharmacology
Downloads 41 (1,170,409)

Abstract:

Loading...

PARP inhibitor, GSK3β, homologous recombination repair, BRCA1, colorectal cancer

2.

Proteasome Inhibitors Reduce Cd73 Expression Partly Via Decreasing P-Erk in Nsclc Cells

Number of pages: 26 Posted: 28 Jul 2023
Ai-Ling Su, Chang-Qing Tian, Ying-Jie Ou, Xu-Bing Bao, Xia-Juan Huan, Ze-Hong Miao and Yingqing Wang
Chinese Academy of Sciences (CAS), Chinese Academy of Sciences (CAS), Chinese Academy of Sciences (CAS), Chinese Academy of Sciences (CAS) - Division of Anti-Tumor Pharmacology, Chinese Academy of Sciences (CAS) - Division of Anti-Tumor Pharmacology, Chinese Academy of Sciences (CAS) - Division of Anti-Tumor Pharmacology and Chinese Academy of Sciences (CAS)
Downloads 38 (1,209,354)

Abstract:

Loading...

CD73, Proteasome inhibitors, ERK, NSCLC